NCT03953014 Pharmacogenetics of Antidepressant-Induced Disinhibition
| NCT ID | NCT03953014 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Calgary |
| Condition | Obsessive-Compulsive Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2019-01-02 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2019-01-02 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.
Eligibility Criteria
Inclusion Criteria: 1. Aged 6 - 24 years 2. Medical records available 3. Diagnosis of MDD, anxiety disorder, or OCD 4. Current or past history of SSRI therapy Exclusion Criteria: 1. Inability of parent/legal guardian to give informed consent 2. Inability of the child to give informed assent 3. Unwillingness of child to provide saliva sample for genetic analysis 4. Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.
Contact & Investigator
Chad Bousman, PhD
PRINCIPAL INVESTIGATOR
University of Calgary
Frequently Asked Questions
Who can join the NCT03953014 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 17 Years, studying Obsessive-Compulsive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03953014 currently recruiting?
Yes, NCT03953014 is actively recruiting participants. Contact the research team at psychpgxlab@ucalgary.ca for enrollment information.
Where is the NCT03953014 trial being conducted?
This trial is being conducted at Calgary, Canada.
Who is sponsoring the NCT03953014 clinical trial?
NCT03953014 is sponsored by University of Calgary. The principal investigator is Chad Bousman, PhD at University of Calgary. The trial plans to enroll 120 participants.